April 2011
Volume 52, Issue 14
ARVO Annual Meeting Abstract  |   April 2011
The Use Of The Fluocinolone Acetonide (Retisert) Implant In Patients With Birdshot Choroidopathy
Author Affiliations & Notes
  • Sunil K. Srivastava
    Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio
  • Quan D. Nguyen
    Diseases of the Retina, and Uveitis, Johns Hopkins Univ,Wilmer Eye Inst, Baltimore, Maryland
  • David Callanan
    Texas Retina Associates, Arlington, Texas
  • Debra A. Goldstein
    Ophthalmology, Univ of Illinois at Chicago, Chicago, Illinois
  • Thomas A. Albini
    Ophthalmology, Bascom Palmer Eye Institute, Miami, Florida
  • Footnotes
    Commercial Relationships  Sunil K. Srivastava, Alimera (C), Allergan (C), Bausch and Lomb (C), Novartis (C); Quan D. Nguyen, Bausch and Lomb (C); David Callanan, Bausch and Lomb (C); Debra A. Goldstein, Bausch and Lomb (C); Thomas A. Albini, Bausch and Lomb (C)
  • Footnotes
    Support  Bausch and Lomb unrestricted grant
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 2751. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Sunil K. Srivastava, Quan D. Nguyen, David Callanan, Debra A. Goldstein, Thomas A. Albini; The Use Of The Fluocinolone Acetonide (Retisert) Implant In Patients With Birdshot Choroidopathy. Invest. Ophthalmol. Vis. Sci. 2011;52(14):2751.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

To describe the clinical outcomes of the subgroup of patients with birdshot choroidopathy enrolled in the fluocinolone acetonide (Retisert) randomized clinical trials.


Data from 3 separate randomized controlled clinical trials performed from 2000-2005 was compiled. Patients with evidence of birdshot choroidopathy were identified from the data set and analyzed. Outcome measures analyzed included recurrence rates, ETDRS visual acuity, time to first recurrence, visual fields, angiographic evidence of leakage and ERG.


A total of 39 patients were identified, 31 patients were randomized to receive fluocinolone acetonide implantation and 8 randomized to standard of care (SOC) medications. Only one eye from each group was used as the study eye. Data was also collected on the fellow eye in the implant group. The average patient age was 46. 26 patients were female, 13 were male. Logmar baseline vision in the implant group was .5067, in the standard of care group was .635 and the fellow eye of the implant group was .2467. 36 month visual acuity results revealed stabilization in the implant group and worsening in both the SOC and fellow eye groups. Recurrence rates over 3 years in the implant group was 22%, 62% in the SOC group and 46% in the fellow eye group. Average time to recurrence was 603 days in the implant group, 430 days in the SOC group and 118 days in the fellow eye group.


In the subgroup of patients with birdshot choroidopathy, eyes implanted with the fluocinolone acetonide implant maintained stable vision over a period of 36 months with a lower recurrence rate and longer time to recurrence in comparision to eyes treated with standard of care medications and fellow non-implanted eyes. This study is limited by the small number of patients, but represents one of the largest series examining the use of the fluocinolone acetonide implant in birdshot patients.

Clinical Trial:

http://www.clinicaltrials.gov NCT00407082

Keywords: uveitis-clinical/animal model • clinical (human) or epidemiologic studies: outcomes/complications 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.